<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6542">
  <stage>Registered</stage>
  <submitdate>12/04/2012</submitdate>
  <approvaldate>12/04/2012</approvaldate>
  <nctid>NCT01611805</nctid>
  <trial_identification>
    <studytitle>Japanese Phase I of GSK1605786</studytitle>
    <scientifictitle>A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>114472</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK1605786
Treatment: drugs - GSK1605786 Placebo

Experimental: GSK1605786 250mg - Opaque Swedish orange body and cap.

Placebo Comparator: Placebo - Opaque Swedish orange body and cap.

Experimental: GSK1605786 500mg - Opaque Swedish orange body and cap.

Experimental: GSK1605786 1000mg - Opaque Swedish orange body and cap.

Experimental: GSK1605786 500mg in fed - Opaque Swedish orange body and cap.


Treatment: drugs: GSK1605786
Opaque Swedish orange body and cap.

Treatment: drugs: GSK1605786 Placebo
Opaque Swedish orange body and cap.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma concentration</outcome>
      <timepoint>up to 72h post dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse envents</outcome>
      <timepoint>up to 72h post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signe</outcome>
      <timepoint>up to 72h post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical laboratory</outcome>
      <timepoint>up to 72h post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>12 lead ECG</outcome>
      <timepoint>up to 72h post dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy Japanese as

          -  Japanese defined as being born in Japan, having four ethnic Japanese grandparents,
             holding a Japanese passport or identity -Male between 20 and 55 years of age
             inclusive, at the time of signing the informed consent.

          -  Body weight =&gt;50kg and BMI within the range 18.5 - 25 kg/m2 (inclusive).</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Known coeliac disease or positive serologic testing for anti-tTG antibodies (required to
        screen for undiagnosed celiac disease)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>22/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>6/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick</hospital>
    <postcode>2031 - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an double-blind, single dose, four-period, crossover study in Japanese healthy male
      volunteers to assess the pharmacokinetics and safety/tolerability of single doses of
      GSK1605786A. Approximately 24 subjects will receive three treatments of 250, 500, and 1000mg
      GSK1605786 under fasted conditions or 500mg after food intake plus placebo in a dose
      ascending crossover design. Serial pharmacokinetic samples will be collected following each
      dose and safety assessments will be performed. The pharmacokinetics and dose proportionality
      of GSK1605786 after single oral doses of GSK1605786 at the dose levels of 250mg, 500mg and
      1000 mg under fasted conditions will be assessed. In addition, a comparison will be made
      between the pharmacokinetics of GSK1605786 under fed and fasted conditions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01611805</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>